IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v16y2019i12p2097-d239525.html
   My bibliography  Save this article

Chronic Viral Hepatitis Signifies the Association of Premixed Insulin Analogues with Liver Cancer Risks: A Nationwide Population-Based Study

Author

Listed:
  • Chien-Hsieh Chiang

    (Department of Family Medicine, National Taiwan University Hospital & College of Medicine, Taipei 100, Taiwan
    Graduate Institute of Pharmacology, National Taiwan University College of Medicine, Taipei 100, Taiwan
    Department of Community and Family Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin 640, Taiwan)

  • Chia-Sheng Kuo

    (Department of Community and Family Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei 108, Taiwan)

  • Wan-Wan Lin

    (Graduate Institute of Pharmacology, National Taiwan University College of Medicine, Taipei 100, Taiwan)

  • Jun-Han Su

    (Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138, USA)

  • Jin-De Chen

    (Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei 108, Taiwan)

  • Kuo-Chin Huang

    (Department of Family Medicine, National Taiwan University Hospital & College of Medicine, Taipei 100, Taiwan
    Hepatitis Research Center, National Taiwan University Hospital, Taipei 100, Taiwan)

Abstract

This study sought to determine whether chronic hepatitis B or C would modify the association between insulin analogues and hepatocellular carcinoma (HCC) risks. We conducted a nationwide nested case-control study for HCC cases and matched controls from 2003 to 2013 among newly diagnosed type 2 diabetes patients on any antidiabetic agents in Taiwan before and after exclusion of chronic viral hepatitis, respectively. A total of 5832 and 1237 HCC cases were identified before and after exclusion of chronic viral hepatitis, respectively. Incident HCC risks were positively associated with any use of premixed insulin analogues (adjusted odds ratio (OR), 1.27; 95% CI 1.04 to 1.55) among total participants, especially among current users (adjusted OR, 1.45; 95% CI 1.12 to 1.89). However, the association between HCC occurrence and premixed insulin analogues diminished among participants without chronic viral hepatitis (adjusted OR, 1.35; 95% CI 0.92 to 1.98). We also observed a significant multiplicative interaction between chronic viral hepatitis and premixed insulin analogues on HCC risks ( P = 0.010). Conclusions: Chronic viral hepatitis signifies the role of premixed insulin analogues in HCC oncogenesis. We recommend a closer liver surveillance among patients prescribed premixed insulin analogues with concomitant chronic viral hepatitis.

Suggested Citation

  • Chien-Hsieh Chiang & Chia-Sheng Kuo & Wan-Wan Lin & Jun-Han Su & Jin-De Chen & Kuo-Chin Huang, 2019. "Chronic Viral Hepatitis Signifies the Association of Premixed Insulin Analogues with Liver Cancer Risks: A Nationwide Population-Based Study," IJERPH, MDPI, vol. 16(12), pages 1-11, June.
    • Handle: RePEc:gam:jijerp:v:16:y:2019:i:12:p:2097-:d:239525
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/16/12/2097/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/16/12/2097/
    Download Restriction: no
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:16:y:2019:i:12:p:2097-:d:239525. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.